Oyster Point Pharma Inc (OQ:OYST)

Business Focus: Biotechnology & Medical Research

INK Ultra Money Free

Latest 10 SEC filings (by transaction date) for OYST within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 11:59pm ET February 23rd, 2020
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction Volume or Value Price
Feb 5/20 Feb 3/20 Nau Jeffrey Direct Ownership Employee Stock Option (Right to Buy) A - Grant, award or other under Rule 16b-3(d) 211,533  
Feb 5/20 Feb 3/20 Snisarenko John Direct Ownership Employee Stock Option (Right to Buy) A - Grant, award or other under Rule 16b-3(d) 72,648  
Feb 5/20 Feb 3/20 Lochner Daniel Direct Ownership Employee Stock Option (Right to Buy) A - Grant, award or other under Rule 16b-3(d) 72,648  
Nov 5/19 Nov 5/19 Kerins Patrick J Indirect Ownership Common Stock, par value $0.001 per share Form 3 : Initial Statement of Beneficial Ownership of Securities    
Nov 4/19 Nov 4/19 New Enterprise Associates 14, L.P. Direct Ownership Series B Convertible Preferred Stock C - Conversion -1,061,547  
Nov 4/19 Nov 4/19 New Enterprise Associates 14, L.P. Direct Ownership Series A Convertible Preferred Stock C - Conversion -3,606,282  
Nov 4/19 Nov 4/19 New Enterprise Associates 14, L.P. Direct Ownership Common Stock, par value $0.001 per share P - Open market or private purchase 935,000 $16.00
Nov 4/19 Nov 4/19 New Enterprise Associates 14, L.P. Direct Ownership Common Stock, par value $0.001 per share C - Conversion 1,061,547  
Nov 4/19 Nov 4/19 New Enterprise Associates 14, L.P. Direct Ownership Common Stock, par value $0.001 per share C - Conversion 3,606,282  
Nov 4/19 Nov 4/19 Falcon Vision LLC Indirect Ownership Series B Convertible Preferred Stock C - Conversion -884,622  
Sign up or login above to see all SEC filings within the past 6 months.
Latest 10 SEC filings (by filing date) for OYST within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 11:59pm ET February 23rd, 2020
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction Volume or Value Price
Feb 5/20 Feb 3/20 Nau Jeffrey Direct Ownership Employee Stock Option (Right to Buy) A - Grant, award or other under Rule 16b-3(d) 211,533  
Feb 5/20 Feb 3/20 Snisarenko John Direct Ownership Employee Stock Option (Right to Buy) A - Grant, award or other under Rule 16b-3(d) 72,648  
Feb 5/20 Feb 3/20 Lochner Daniel Direct Ownership Employee Stock Option (Right to Buy) A - Grant, award or other under Rule 16b-3(d) 72,648  
Nov 6/19 Nov 4/19 InvOpps GP IV, L.L.C. Indirect Ownership Series B Convertible Preferred Stock C - Conversion -1,230,050  
Nov 6/19 Nov 4/19 InvOpps GP IV, L.L.C. Indirect Ownership Series B Convertible Preferred Stock C - Conversion -609,965  
Nov 6/19 Nov 4/19 InvOpps GP IV, L.L.C. Indirect Ownership Common Stock, par value $0.001 per share P - Open market or private purchase 501,375 $16.00
Nov 6/19 Nov 4/19 InvOpps GP IV, L.L.C. Indirect Ownership Common Stock, par value $0.001 per share P - Open market or private purchase 248,625 $16.00
Nov 6/19 Nov 4/19 InvOpps GP IV, L.L.C. Indirect Ownership Common Stock, par value $0.001 per share C - Conversion 1,230,050  
Nov 6/19 Nov 4/19 InvOpps GP IV, L.L.C. Indirect Ownership Common Stock, par value $0.001 per share C - Conversion 609,965  
Nov 5/19 Nov 5/19 Kerins Patrick J Indirect Ownership Common Stock, par value $0.001 per share Form 3 : Initial Statement of Beneficial Ownership of Securities    
Sign up or login above to see all SEC filings within the past 6 months.
Sign up or login above to see the past 6 months of filings sorted by insider. .
Get holdings trends & enhanced insider charts in PDF now

Twitter

Search (past week) for $OYST

Competitors

Competitors with Recent Insider Filings
Iqvia Holdings (N:IQV)
Alnylam Pharmaceuticals (OQ:ALNY)
Vir Biotechnology (OQ:VIR)